NEWS
  • March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
  • December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
  • January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
  • January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
  • December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
  • April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
  • February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
  • February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
  • December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
S1 Biopharma
  • COMPANY
    • ABOUT US
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • MEDICAL ADVISORY BOARD
  • PIPELINE
    • OREXA
    • LOREXYS
    • S1B-307
    • S1B-3006
  • A New Vision for addressing Sexual Wellness
    • SEXUAL DYSFUNCTION R&D
    • SCIENTIFIC PUBLICATIONS
    • PARTNERING
  • NEWSROOM
    • PRESS RELEASES
    • MEDIA COVERAGE
  • INVESTORS
    • LOGIN
  • CONTACT US

couple-1-s1biopharma

‹ Return to couple-1-s1biopharma

October 3, 2013 admin

Understanding Hypoactive Sexual Desire Disorder Learn More

P882wqIgaSCsTPMWRq0gxa0n1T0FJ1cmzsa4NU11pbc
couple-2-s1biopharma
  • March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
  • December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
  • January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
  • January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
  • December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
Recent Comments
    Archives
    • March 2021
    • December 2019
    • January 2019
    • December 2018
    • April 2016
    • February 2016
    • December 2015
    • November 2015
    • June 2015
    • March 2014
    • October 2013
    • August 2013
    • July 2013
    • May 2013
    • February 2013
    • May 2012
    • April 2012
    • March 2012
    • February 2012
    • October 2011
    Categories
    • Erectile Dysfunction
    • EVENTS
    • FDA
    • FSD
    • HSDD
    • LOREXYS
    • MEDIA COVERAGE
    • NEWS
    • OREXA
    • PRESS RELEASES
    • S1B-3006
    • S1P-205
    • scientific publications
    Meta
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • CONTACT US
    • SITE MAP
    • Terms of Use
    • © S1 biopharma Inc.
    S1 Biopharma, Inc.
    7 World Trade Center
    250 Greenwich St.
    46th Floor
    New York City, NY 10007
    Email: info@s1biopharma.com